Evidence map›Paper›PMID 30293216›Full record

ArticleClinical and experimental nephrology2019

Clinical significance of mesangial IgM deposition in patients with IgA nephropathy.

Cihan Heybeli, Mehmet Ası Oktan, Serkan Yıldız, Hayri Üstün Arda, Mehtat Ünlü, Caner Çavdar, Aykut Sifil, Ali Çelik, Sülen Sarıoğlu, Taner Çamsarı

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Contemporary review of IgA nephropathy.Frontiers in immunology · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Cihan HeybeliDivision of Nephrology, Department of Internal Medicine, School of Medicine, Dokuz Eylul University, Balçova, İzmir, Turkey. heybelic@hotmail.com.
Mehmet Ası OktanDivision of Nephrology, Department of Internal Medicine, School of Medicine, Dokuz Eylul University, Balçova, İzmir, Turkey.
Serkan YıldızDivision of Nephrology, Department of Internal Medicine, School of Medicine, Dokuz Eylul University, Balçova, İzmir, Turkey.
Hayri Üstün ArdaDivision of Nephrology, Department of Internal Medicine, School of Medicine, Dokuz Eylul University, Balçova, İzmir, Turkey.
Mehtat ÜnlüDepartment of Pathology, School of Medicine, Dokuz Eylul University, İzmir, Turkey.
Caner ÇavdarDivision of Nephrology, Department of Internal Medicine, School of Medicine, Dokuz Eylul University, Balçova, İzmir, Turkey.
Aykut SifilDivision of Nephrology, Department of Internal Medicine, School of Medicine, Dokuz Eylul University, Balçova, İzmir, Turkey.
Ali ÇelikDivision of Nephrology, Department of Internal Medicine, School of Medicine, Dokuz Eylul University, Balçova, İzmir, Turkey.
Sülen SarıoğluDepartment of Pathology, School of Medicine, Dokuz Eylul University, İzmir, Turkey.
Taner ÇamsarıDivision of Nephrology, Department of Internal Medicine, School of Medicine, Dokuz Eylul University, Balçova, İzmir, Turkey.
Dokuz Eylül University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlomerular immunoglobulin G deposition in patients with immunoglobulin A nephropathy (IgAN) has been shown to be associated with adverse renal outcomes. Clinical significance of mesangial immunoglobulin M (IgM) deposition in these patients remains to be proven.

methodsOne hundred patients who had a diagnosis of IgAN between 2001 and 2017 were enrolled. Patients were divided into two groups based on mesangial IgM deposition status. Groups were compared for demographic, clinical, and pathologic variables at baseline and in follow-up. Cox regression analysis was performed to evaluate the effect of mesangial IgM positivity on renal survival.

resultsIgM-positive group included 51% of participants. Baseline demographic and clinical parameters were not significantly different between groups. Mesangial IgM deposition was significantly associated with a higher segmental sclerosis score (p = 0.008). At last visit, median serum creatinine was higher (p = 0.021) and eGFR was lower (p = 0.006) in IgM-positive group. Nineteen (19%) of all patients reached the combined primary outcome which includes doubling in serum creatinine or evolution to ESRD. Cumulative renal survival was lower (p = 0.001) and resistant disease was more frequent in IgM-positive group (p = 0.026). Renal survival at 15 years was 94.2% and 59.7% in IgM-negative and IgM-positive groups, respectively (p = 0.006). Time-averaged proteinuria (HR 2.9; 95% CI 1.9-4.5; p < 0.001) and mesangial IgM deposition (HR, 13.2; 95% CI 1.9-93.1; p = 0.01) were found to be independent predictors of unfavorable renal outcomes.

conclusionsIn conclusion, we demonstrated that mesangial IgM deposition independently associated with worse renal outcomes in patients with IgA nephropathy.

Indexed as

AdultCreatinineDisease ProgressionFemaleGlomerular Filtration RateGlomerular MesangiumGlomerulonephritis, IGAHumansImmunoglobulin MKidney Failure, ChronicMaleMiddle AgedProportional Hazards ModelsCreatinineImmunoglobulin MEnd-stage renal diseaseIgA nephropathyIgM

Identifiers

PMID30293216
OpenAlexW2895271624

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.